Dendreon Corp

  • This Biotech’s Single Egg Will Never Hatch

    By Leo Sun - August 16, 2013 | Tickers: DNDN, JNJ, MDVN

    Shares of Dendreon (NASDAQ: DNDN) have taken a beating over the past month, falling more than 30% over the past week after sales of its prostate cancer therapy Provenge fell short of analyst estimates. Dendreon’s decline illustrates a classic dilemma in biotech investing -- what happens when a company only has a single egg in its basket, and that egg fails to hatch?

    The single egg cracks

    Dendreon only has more »

  • Biotechs With Prostate Cancer Treatments

    By Terry Chrisomalis - July 31, 2013 | Tickers: DNDN, JNJ, MDVN

    There are many types of biotech companies out there with tremendous value. Today, I will focus on the ones that target prostate cancer. Investors should look at these types of companies as they are starting to make good progress on their research. Another reason is that there is a huge billion dollar opportunity in this sector.

    When I say a billion dollar opportunity, I mean it literally. The sector is more »

  • Is Time Running Out for This Fallen Biotech?

    By Sherrie Stone - July 17, 2013 | Tickers: DNDN, JNJ, MDVN

    There’s a lot to notice from Johnson & Johnson’s (NYSE: JNJ) earnings -- the company announced a very solid quarter. But the one thing that really stood out is the high sales that the company produced from its prostate cancer drug Zytiga. Does Zytiga's succes further indicate that time is running out for Dendreon’s (NASDAQ: DNDN) Provenge?

    Zytiga’s not slowing down

    Johnson & Johnson’s total sales for more »

  • Ahead of an FDA Decision, Do You Buy This Stock?

    By Sherrie Stone - July 12, 2013 | Tickers: ALXN, DNDN, PCYC

    Pharmacyclics (NASDAQ: PCYC) crossed $100 a share on Thursday, giving it a market cap of $7.4 billion and a one-year return of 73%. As the company prepares to seek FDA approval for its oncology drug candidate ibrutinib, has its valuation become too large to justify your investment?

    Promising Yet Expensive

    Pharmacyclics is at a crucial point in its history: It is seeking an FDA approval to treat mantle cell more »

  • Why You Shouldn’t Bet On This Product Launch Yet

    By Sherrie Stone - July 10, 2013 | Tickers: AMRN, DNDN

    For the last few weeks, there has been a heated debate regarding the success or lack thereof from biotechnology company Amarin's (NASDAQ: AMRN) new product launch. Those who are bullish note encouraging month-over-month script growth in the thousands for the cardiovascular drug Vascepa. However, as the company issues even more shares to fund Vascepa's marketing, is it still worth an investment?

    Month

    Scripts Written

    Month-Over-Month % Gain

    February

    3 more »

  • Is The DMD Market Becoming Too Crowded?

    By Sherrie Stone - July 10, 2013 | Tickers: DNDN, GSK, PTCT, SRPT

    A year ago, AVI BioPharma underwent a process from being an $85 million biotechnology company to a $1.3 billion company called Sarepta Therapeutics (NASDAQ: SRPT). All of this was possible with just one product (eteplirsen), 12 patients, and an exon-skipping technology that is producing unprecedented results and creating buzz on Wall Street.

    What’s creating the buzz?

    Sarepta Therapeutics saw one of the biggest single day jumps of 2012 more »

  • Beware the Bullishness on Bristol-Myers

    By Bob Chandler - June 15, 2013 | Tickers: BMY, DNDN, MRK

    A new drug in the fight against cancer is certainly an exciting and welcome development. Unfortunately, in many cases, the news often pushes the stock price of the company involved to overly enthusiastic heights. While the optimism about the drug may be fully justified, some investor caution on the stock may be prudent.

    Recent news about Bristol-Myers Squibb's (NYSE: BMY) latest oncology drug candidate might be such a case more »

  • A Promising Platform for Cancer Immunotherapy

    By Seth Robey - June 10, 2013 | Tickers: BMY, CLDX, DNDN, MRK

    A 2011 Nobel Prize in Physiology and Medicine is certainly impressive.  Using a novel cancer treatment on yourself is both impressive and courageous.  Dr. Ralph Steinman believed so enthusiastically in the cancer vaccines which he helped to develop that he used many of them to treat his own pancreatic cancer.  Surviving for five additional years, Steinman was able to use his position on the Scientific Advisory Board of Celldex (NASDAQ: CLDXmore »)

  • Why Questcor Is Undervalued

    By Ishtiaq Ahmed - May 8, 2013 | Tickers: DNDN, QCOR, SRPT

    Questcor Pharmaceuticals (NASDAQ: QCOR) has faced the affects of bad press more than once in the past. The stock lost more than half of its value last year, after reports about its questionable marketing practices spurred a federal investigation. While that drop was extremely painful for long-term investors, it gave speculators and short-term traders an opportunity to make substantial profits, and let long-term investors add to their positions. The stock more »

  • Galena: Improving Cancer Vaccines for the Future

    By Terry Chrisomalis - May 7, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for breast cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Galena Improving Cancer Vaccines For The Future

    By Terry Chrisomalis - May 1, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for Breast Cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Is Medivation Still A Buy?

    By Terry Chrisomalis - April 18, 2013 | Tickers: DNDN, JNJ, MDVN

    It seems that Medivation (NASDAQ: MDVN) had a great year in 2012, and so far the momentum seems it will keep going through all of 2013 as well. Medivation is a biotechnology stock that targets diseases with limited treatment options. The company had a rough past when it had partnered with Pfizer, with a drug known as Dimebon. 

    Dimebon had made it up to Phase III, where it had failed more »

  • Should You Sell These Biotechnology Stocks

    By Mohsin Saeed - April 14, 2013 | Tickers: CBM, DNDN, IDIX

    Bio-pharmaceutical companies usually make for some very high risk investments. This is because there are a number of factors that cannot be predicted accurately.The valuations skyrocket on drug approvals, but the actual performance in the market is an entirely different story. The following three stock have seen heavy institutional selling in the last few months, and I believe investors should stay away from them for the time. 

    Cambrex Corporation more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 10, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Is Medivation Still A Buy?

    By Terry Chrisomalis - April 9, 2013 | Tickers: DNDN, JNJ, MDVN

    It seems that Medivation (NASDAQ: MDVN) had a great year in 2012, and so far the momentum seems it will keep going through all of 2013 as well. Medivation is a biotechnology stock that targets diseases with limited treatment options. The company had a rough past though, when it had partnered with Pfizer with a drug known as Dimebon. 

    Dimebon had made it up to phase three, where it had more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 8, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • A Magical Drug that Could Change Lives

    By Piyush Arora - March 25, 2013 | Tickers: DNDN, JNJ, MDVN

    The biotech sector is perhaps the most volatile and risk-prone sector in the market, but investors still love it. Medical science is leaping forward and new drugs keep hitting the Street, but the hunt for the “safer and more effective drug” is always on. It’s for this reason that we often see contrarians being rewarded massively for their daring positions. The company in focus is Dendreon Corporation (NASDAQ: DNDNmore »)

  • Revitalize Your Portfolio With This Drugmaker

    By Rahul Giria - March 11, 2013 | Tickers: DNDN, MDVN, NVS

    Dendreon (NASDAQ: DNDN) has been struggling since summer 2011, when the company decreased its sales estimates for its flagship cancer drug Provenge. As a result, shares have taken a huge hit since then. Provenge faces stiff competition from Medivation’s (NASDAQ: MDVN) Xtandi and Johnson & Johnson’s (NYSE: JNJ) Zytiga. Yet I believe now's the right time to invest in Dendreon's stock. Let assess why.

    Financials

    Dendreon surprised more »

  • Should you Buy this Company on Earnings?

    By Mohsin Saeed - March 5, 2013 | Tickers: ALPMY.PK, DNDN, JNJ

    Dendreon Corp. (NASDAQ: DNDN) investors have been on a perpetual roller coaster ride due to shifting expectations from Provenge. The company reported its quarterly results the other day and beat Street estimates. However, Provenge faces severe competition from Astellas’ (NASDAQOTH: ALPMY) Xtandi and Johnson & Johnson’s (NYSE: JNJ) Zytinga. I believe that despite the recent positives it’s still too soon to be bullish on Dendreon, and I advise investors more »

  • Are Any of these Stocks Worth Buying After Earnings?

    By Brian Nichols - February 28, 2013 | Tickers: DDD, DNDN, LOW

    Earnings and earning-related news is the number one catalyst for stock movement. A strong quarter can dictate the direction of a stock for the following three months as can a bad quarter; in the past I have written in detail about such subjects, a domino effect following a strong or bad quarter. In this piece I am looking at three stocks with high profile earning releases. Then, I am determining more »

  • Page 1 of 4